Patent Granted to Aquavit for Novel RoA and MoA for Bioactive Compositions
News provided by
Share this article
Share this article
NEW YORK, May 4, 2021 /PRNewswire/ U.S. patent number 10,980,865 [Application Number 14/909,954] was granted to Aquavit Pharmaceuticals, Inc. for
direct application system and method for the delivery of bioactive compositions and formulations. The invention utilizes a repeated motion delivery technology (AQT Technology), creating a new route of administration (RoA) and mode of administration (MoA) for the pharmaceutical and biotechnology industry for the first time in decades.
“This patent combined with our recent acquisition of a License for a new botulinum toxin asset will ignite many advancements in the industry and provide limitless opportunities for New Drug Applications (NDA) or Biologics License Applications (BLA).” says Sobin Chang, MPH., CEO of Aquavit.